Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Neuroone Medical Technologies (NMTC) Change in Acquisitions & Divestments (2022 - 2023)

Neuroone Medical Technologies' Change in Acquisitions & Divestments history spans 2 years, with the latest figure at $1.0 million for Q2 2023.

For Q2 2023, Change in Acquisitions & Divestments changed N/A year-over-year to $1.0 million; the TTM value through Sep 2023 reached $4.5 million, changed N/A, while the annual FY2023 figure was $4.5 million, 800.0% up from the prior year.
Change in Acquisitions & Divestments reached $1.0 million in Q2 2023 per NMTC's latest filing, down from $2.0 million in the prior quarter.
In the past five years, Change in Acquisitions & Divestments ranged from a high of $2.0 million in Q1 2023 to a low of $1.0 million in Q2 2023.